POP Biotechnologies specializes in developing innovative nanotechnology solutions aimed at addressing significant challenges in oncology and infectious diseases. The company utilizes two patented porphyrin-phospholipid (PoP) liposome technologies to create advanced nanomedicines. One of their key platforms, the Spontaneous Nanoliposome Antigen Particleization (SNAP) technology, facilitates the rapid development of highly immunogenic vaccines. This platform allows for the seamless incorporation of His-tagged antigens into liposomes, resulting in stable nanoparticle vaccines that can elicit robust immune responses. The SNAP technology not only streamlines the vaccine development process but also enhances the immune response, making it particularly effective for multivalent immunization.

In addition to vaccine development, POP Biotechnologies is advancing targeted chemotherapy through Chemophototherapy (CPT), which employs PoP liposomes to deliver chemotherapy drugs directly to tumors when exposed to specific laser light. This targeted approach aims to improve the efficacy of chemotherapy while minimizing side effects. The company is actively engaged in clinical trials for various products, including a shingles vaccine developed in collaboration with EuBiologics, showcasing the versatility and potential of their proprietary technologies in creating next-generation therapeutics and vaccines.

United States

POP Biotechnologies, Inc is Buffalo NY biotechnology company focused on the development of innovative biomedical solutions harnessing next generation nanotechnologies.

POP Biotechnologies

Company Details